Venaxis to Provide Fourth Quarter 2012 Business Update

            Venaxis to Provide Fourth Quarter 2012 Business Update

Conference Call and Webcast scheduled for March 26, 2013, 4:30 p.m. ET

PR Newswire

CASTLE ROCK, Colo., March 19, 2013

CASTLE ROCK, Colo., March 19, 2013 /PRNewswire/ --Venaxis, Inc. (Nasdaq:
APPY), an in vitro diagnostic company focused on obtaining FDA clearance and
commercializing its rapid, protein biomarker-based appendicitis test, APPY1,
today announced it will provide a fourth quarter business update on Tuesday,
March 26, 2013, at 4:30 p.m. ET. The conference call will be hosted by Steve
Lundy, Chief Executive Officer; Jeff McGonegal, Chief Financial Officer; and
Don Hurd, Senior Vice President and Chief Commercial Officer.

Interested participants and investors may access the conference call by
dialing 1-800-860-2442 (U.S.), 1-866-605-3852 (Canada) or 1-412-858-4600
(international). A live audio webcast will be accessible via the Investor
Relations section of the Venaxis web site,

A telephonic replay of the call will be available for 30 days beginning at
8:00 p.m. ET on March 26, 2013. Access numbers for this replay are
1-877-344-7529 (U.S./Canada) and 1-412-317-0088 (international); conference
ID: 10026445. The webcast replay will remain available in the Investors
Relations section of the Venaxis web site for 30 days.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its CE-Marked rapid, protein
biomarker-based appendicitis test, APPY1. This unique appendicitis test has
projected high sensitivity and negative predictive value and is being
developed to aid in the identification of patients at low risk for acute
appendicitis, allowing for more conservative patient management. APPY1 is a
CE Marked product in Europe and is being developed in the U.S. initially for
pediatric, adolescent and young adult patients with abdominal pain, as this
population is at the highest risk for appendicitis and has the highest risk of
long-term health effects associated with CT imaging. While FDA clearance is
being sought, an initial launch for APPY1 is ongoing in select European
territories. For more information, visit

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking statements.
These statements are based on certain assumptions made based on experience,
expected future developments and other factors Venaxis believes are
appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of
Venaxis. Investors are cautioned that any such statements are not guarantees
of future performance. Actual results or developments may differ materially
from those projected in the forward-looking statements as a result of many
factors, including our ability to successfully complete required product
development and modifications in a timely and cost effective manner, complete
clinical trial activities for APPY1 required for FDA submission, obtain FDA
clearance or approval, maintain CE Marking, cost effectively manufacture and
generate revenues from APPY1 at a profitable price point, execute agreements
required to successfully advance the company's objectives, retain the
management team to advance the products, overcome adverse changes in market
conditions and the regulatory environment, obtain and enforce intellectual
property rights, and realize value of intangible assets. Furthermore, Venaxis
does not intend (and is not obligated) to update publicly any forward-looking
statements. The contents of this press release should be considered in
conjunction with the risk factors contained in Venaxis' recent filings with
the SEC, including its Form 10-Q for the period ended September 30, 2012,
filed on November 7, 2012.

For Investors and Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, PhD; (212) 375-2664
Jason Rando; (212) 375-2665

SOURCE Venaxis, Inc.

Press spacebar to pause and continue. Press esc to stop.